Amendment No. 1 to Warrant Agreement between Molecular Diagnostics, Inc. and Investors

Contract Categories: Business Finance › Warrant Agreements
Summary

This amendment, dated August 19, 2002, modifies the original Warrant Agreement between Molecular Diagnostics, Inc. and its investors. The main change is a reduction in the exercise price of the warrants from $0.65 to $0.25 per share. The amendment is made in connection with a prior bridge financing and is executed by both the company and the investors. All other terms of the original warrant remain unchanged.

Read More Arrow
EX-4.36 3 exhibit436.txt EXHIBIT 4.36 Exhibit 4.36 AMENDMENT NO. 1 TO THE WARRANT This Amendment No. 1, dated as of August 19, 2002 (this "Amendment No. 1"), is to the Warrant, dated as of July 30, 2002, (the "Warrant") between Molecular Diagnostics, Inc., a Delaware corporation (the "Company"), and the holders of the Warrants (the "Investors"). WITNESSETH: WHEREAS, the Investors purchased the Warrants in connection with a bridge financing that closed June 30, 2002; WHEREAS, the Investors have agreed to amend the maturity date of certain Promissory Notes purchased in the bridge financing; and WHEREAS, pursuant to and in compliance with the provisions of Section 21 of the Warrants, the Company and the Investors desire to amend the Warrants as hereinafter set forth. NOW, THEREFORE, in consideration of the premises and agreements herein contained, the Company and the Investors agree as follows: 1. The Exercise Price of the Warrants is adjusted from $0.65 per share to $0.25 per share. 2. Capitalized terms not defined herein shall have the meanings given them in the Warrants. 3. This Amendment No. 1 may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. IN WITNESS WHEREOF, the parties have caused this Amendment No. 1 to be duly executed and attested as of the ____ day of August, 2002. MOLECULAR DIAGNOSTICS, INC. By: _________________________________ Name: Peter P. Gombrich Title: Chief Executive Officer and President INVESTOR: By: _________________________________